Evidence to Support a Putative Role for Insulin Resistance in Chronic Kidney Disease by Shehab-Eldin, W et al.
27
* Corresponding author; Director of Transplant Program, Department of 
Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, 
SK S7N 0W8, Canada; E mail: ass787@mail.usask.ca
Arab Journal of Nephrology and Transplantation. 2009 Sep;2(3):27-36
Review Article AJNT
Abstract
Introduction: The primary cause of morbidity and 
mortality in the renal patient is a cardiovascular event. 
Insulin resistance (IR) contributes to this event by 
increasing cardiovascular disease (CVD) and accelerating 
rates of decline in kidney function. Here we review the 
historical background of IR in patients with chronic 
kidney disease (CKD) and present evidence for a role of 
IR in accelerating cardiovascular and renal diseases.
Review: The high prevalence of IR in CKD patients is 
well documented. It is suggested that increased IR in the 
renal patient is caused by uremia as well as by other known 
factors in the general population. Patients with CKD have 
an alarmingly high risk for cardiovascular morbidity and 
mortality. There is overwhelming evidence to support a 
role for IR in increased CVD morbidity and mortality in 
the general population, which is likely to extend to CKD 
patients. Some of the traditional treatment measures for 
IR, such as metformin, may not be applicable to the renal 
patient. Other options include weight reduction, exercise, 
treatment of anemia to improve exercise tolerance, 
treatment of vitamin D deficiency, thiazolidinediones, 
and dialysis. IR is estimated by studying the relationship 
between blood glucose and the concomitant insulin 
level. Such measurement may help identify patients at 
increased risk for future cardiovascular events and guide 
treatment measures.
Conclusion: Sufficient evidence supports the increased 
prevalence of IR in kidney patients. Treating IR may 
retard the progression of CKD and decrease the incidence 
of cardiovascular events in this high risk population. 
Keywords: chronic kidney diseass, cardiovascular 
disease, insulin resistance
Introduction
Insulin resistance (IR) is defined as a state of diminished 
responsiveness of many tissues to insulin. To overcome 
the diminished responsiveness to insulin action, the 
pancreas responds by producing more insulin, reaching 
a new steady state at which a higher than normal 
insulin level is needed to maintain internal homeostasis. 
Meanwhile, the kidney and blood vessels maintain a 
normal response to insulin, so as a result these important 
organs are negatively affected by the increased insulin 
level. Thus, IR manifests itself in two complementary 
pathological sets of derangements. First, manifestations 
occur due to IR in certain tissues such as the muscles and 
adipose tissues. Second, heightened responses by other 
organs occur due to the increased insulin level such as the 
kidney and blood vessels.
IR in humans was first described in 1939 by Himsworth, 
who speculated that diabetes mellitus may result 
from insensitivity to insulin action as well as from its 
deficiency. In 1949 he documented IR in patients with 
diabetes mellitus. In 1979 Defrenzo et al developed the 
hyperinsulinemic euglycemic clamp as the gold standard 
method for diagnosis of IR. Sex years later, Mathew et 
al developed a variety of mathematical equations based 
on fasting insulin and blood sugar levels to estimate IR. 
Quantitative Insulin Sensitivity Check Index (QUICKI) 
is a more recent equation for estimation of  IR in 
epidemiological studies [1].
The presence of IR in uremia is well documented. In 
1969, Westervelt reported IR in patients with uremia. In 
1981 Defronzo et al presented an argument to support 
adipose tissue insensitivity as the primary site of failure 
to insulin action in renal patients with IR. In 1996, Dengal 
et al suggested a role of IR as a risk factor that accelerates 
the rate of decline in kidney function.
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Figure 1: The bi-directional relationship of IR and CKD and their combined effect on the cardiovascular system
IR: insulin resistance; GFR: glomerular filtration rate; IGF-1: Insulin-like Growth Factor-1; PAI-1: Plasminogen Activator Inhibitor-1; TGF-β: 
transforming growth factor-beta; RAS: renin-angiotensin system; CRP: C-reactive protein; FFA: free fatty acids; IL-6: interleukin-6;  IL-1β: interleukin-
1β; IKK-β: inhibitor of kappaB kinase beta ; VLDL: very low density lipoprotein; HGP: hepatic glucose production; NO: nitrous oxide
Arab Journal of Nephrology and Transplantation
29
Insulin resistance in CKD
The prevalence and risks of IR in patients with 
cardiovascular diseases (CVD) also has been well 
documented. In 1977, Stout suggested that IR is an 
important component of the metabolic syndrome. He 
reported IR as a significant risk factor for cardiovascular 
morbidity and mortality. Shinohara, Foley, and Mann 
and their co-workers reported a role of IR in increased 
cardiovascular events in patients with chronic kidney 
disease CKD [2, 3]. Despite all the above-listed reports, 
current guidelines for the routine follow-up of patients 
with CKD do not include IR measurement.  
Based on the above reports, however, we believe that 
measuring serum insulin and estimating IR should be a 
welcomed additional laboratory test in managing patients 
with CKD. This review, therefore, serves to delineate 
our rationale to recommend the measurement of serum 
insulin and estimate IR in CKD patients. 
Role of IR in accelerating rate of decline in 
renal function
IR is well documented in patients with CKD and end 
stage renal disease (ESRD) [4]. Epidemiological studies 
suggested a significant correlation between IR and CKD. 
Chen et al suggested that Homeostatic Model Assessment 
of Insulin Resistance (HOMA-IR) increased by 1.93 is 
associated with a 1.5 hazard ratio of CKD prevalence [5]. 
Onat et al suggested that doubling HOMA-IR in men is 
associated with a 14% reduction in Glomerular Filtration 
Rate (GFR) [6]. More recently, it was suggested that 
HOMA-IR correlates with interstitial fibrosis diagnosed 
by renal biopsy (R = 0.42, P = 0.04) [7]. Moreover, IR was 
found to precede the development of microalbuminuria, 
a known potent risk factor for accelerating both CKD and 
CVD.
Few studies looked at the prevalence of IR in renal 
patients. It was reported that 48.3% of non-diabetic, 
non-obese patients with CKD [8] and 31.6% of 
hemodialysis (HD) patients [9] have IR. Recently, the 
prevalence of IR was estimated at 47.8% of renal patients 
[7]. Three main hypotheses explain the higher prevalence 
of IR in kidney disease. First, IR may be causally related 
to CKD [5]. Secondly, IR may be a consequence of CKD. 
Thirdly, both IR and CKD occur as consequences of a 
same process, for example metabolic syndrome [10]; and 
there is yet the possibility of a bi-directional relationship 
between IR and CKD that leads to progression in kidney 
failure.
It is suggested that increased IR in the renal patient is 
caused by uremia as well as by other known factors in the 
general population [11] (Figure 1). Fliser et al documented 
the presence of IR even in renal patients with normal GFR. 
They described an association between increased IR and 
progression of kidney disease in two groups of patients 
with Adult Polycystic Kidney Disease (APKD) and IgA 
nephropathy. Vareesangthip and co-workers reached 
Table 1: Factors which may modify IR in the renal patient [4, 11-22]
Renal risk factor Effect
Type of kidney Disease APKD ↑↑
IGA nephropathy ↑↑
Glomerulonephritis ↑↑
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a similar conclusion in another cohort of patients with 
APKD. Kato et al documented increased IR in patients 
with glomerulonephritis diagnosed by renal biopsy even 
with normal serum creatinine [4].
Several types of kidney diseases are associated with 
IR and potential modifying effects (Table 1). Steroids, 
diuretics, and beta blockers are well documented risk 
factors for increased IR in renal patients. It should be 
noted that 1,25 dihydroxycholecalciferol, statins, ACE 
inhibitors, Prazocin, Nifedipine, and Erythropoietin were 
found to improve sensitivity to insulin. Both hemodialysis 
and peritoneal dialysis improve insulin sensitivity, while 
renal transplantation aggravates resistance to insulin. 
Several mechanisms are suggested to explain the 
deterioration of renal function with increasing IR. In 
the general population, insulin has both vasodilator and 
salt-retaining effects, leading to an increase in the renal 
blood flow and GFR [23]. In IR, This effect is reversed 
and insulin leads to the reduction in GFR [24]. High-dose 
insulin infusion increases the renal albumin excretion in 
diabetic patients by about 50% without affecting systemic 
albumin permeability. On the other hand, a high insulin 
dose doesn’t affect renal albumin excretion in healthy 
individuals, thus providing evidence of the contribution 
of insulin in renal injury in IR states. High insulin may 
also lead to renal injury by stimulating different mediators 
implicated in the progression of kidney disease including 
Insulin-like Growth Factor-1 (IGF-1), Transforming 
Growth Factor-β (TGF-β), and plasminogen activator 
inhibitor-1 (PAI-1) [25].
Hyperinsulinemia increases angiotensin II-mediated 
aldosterone secretion and increases the pressor effect of 
angiotensin II by increasing activation of the sympathetic 
nervous system. In addition, insulin is necessary for the 
angiotensin II-induced contraction of mesangial cells, 
which is another link proving insulin- and angiotensin 
II-mediated renal injury. IR may also cause renal injury 
through the inhibition of NO synthesis, which is a known 
renal vasodilator molecule [26]. 
Insulin enhances oxidative stress both through down-
regulation of anti-oxidative enzymes and through 
stimulating free radical production [27]. Oxidative stress 
is implicated in the progression of CKD [28].
Low HDL cholesterol observed in IR (as discussed 
before) was found as an independent predictor of kidney 
disease progression among 840 patients with CKD in the 
MDRD study. Hypertriglyceridemia and low HDL were 
found to predict and increase the risk of CKD in 12,728 
participants in the “Atherosclerosis Risk in Communities” 
study [29].
Insulin resistance as a risk factor for CVD in 
renal patients
Patients with CKD have an alarmingly high risk for 
cardiovascular morbidity and mortality. This applies even 
to patients with minor degrees of renal dysfunction [30]. 
In fact, most CKD patients die before reaching ESRD. 
Many investigators have presented a plethora of evidence 
to support a role for IR in increased CVD morbidity 
and mortality in the general population. Paradoxically, 
few researchers studied this correlate in CKD patients. 
We reason, therefore, that the evidence in the general 
population is so overwhelming and, by extension, urgent 
studies are needed to address the role of IR and its 
treatment in CKD patients.
Table 2: Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and/or Hazard Ratio (HR) in renal and non-renal 
patients with and without CVD [3, 8, 13, 16, 41-47]
Non-CKD population CKD Population
Control CVD Diabetics No CVD CVD Diabetics
HOMA-IR Number HOMA-IR Number HOMA-IR Number HOMA-IR Number HOMA-IR Number HOMA-IR Number
2.5 721 2.8 118 -- -- -- -- -- -- -- --
2.54 36 -- -- -- -- 2.88 95 -- -- -- --
1.7 25 -- -- -- -- 6.87 239 -- -- -- --
2.9 25 -- -- -- -- 6 52 -- -- -- --
-- -- -- -- -- -- 5.46 89 -- -- -- --
1.39 76 -- -- -- -- 3.38 199 5.12 28 -- --
-- -- -- -- -- -- 2.4 35 -- -- 6.3 27
-- -- HR: 2.5 2569 HR: 1.56 1326 -- -- HR: 2.61 -- -- --
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Mechanisms by which IR increases risk 
of CVD 
1. Insulin resistance and hypertension
Increased insulin level enhances sympathetic activity, 
sodium retention, and proliferation of vascular smooth 
muscle cells. IR leads also to hyperglycemia, which 
inhibits the ADMA/DDAH pathway and thereby inhibits 
nitric oxide production [31].
2. Insulin resistance and atherosclerosis
Both the increased insulin level and the associated 
hyperglycemia are suggested culprits for enhancing 
atherosclerosis. A direct role of insulin in atherogenesis 
has been suggested from animal studies. Mechanistically, 
insulin leads to the induction of proliferation of VSMCs, 
switching the genes involved in connective tissue 
formation, upregulation of LDL-receptor activity and 
stimulation of the production of growth factors. On the 
other hand, the associated hyperglycemic inhibitory 
effect on NO [31] explains the endothelial dysfunction 
associated with IR. In addition, the resistance of the 
adipose tissue to insulin leads to the release of several 
inflammatory mediators such as IL-6 [32] and TNFα [33]. 
These mediators are known to directly affect migration 
of macrophages into the sub-endothelial layer leading 
to foam cell formation with the CD-36 receptor, which 
internalizes oxidized LDL [34].
3. Insulin resistance and thrombosis
Hyperinsulinemia induces endothelial dysfunction and 
enhances release of several inflammatory mediators, 
both of which are known to enhance the synthesis and 
production of several pro-coagulant factors such as von 
Willebrand factor (vWF), factor VIII, factor XII, factor 
VII, and fibrinogen. PAI-1 production is increased, 
likely in response to IGF-1 and TGF-β. Hyperglycemia 
and increased free fatty acid (FFA) production impair 
fibrinolysis by similar mechanisms [35].
4. Insulin resistance and left ventricular function
Left ventricular hypertrphy (LVH) has been associated 
with diabetes mellitus and abnormal glucose tolerance 
in several epidemiological investigations [36]. LVH is 
common with other endocrinal disorders associated with 
IR such as acromegaly and hypothyroidism [37].
Increased circulating FFAs associated with hyperglycemia 
in IR results in a series of metabolic adaptations and 
maladaptations that eventually result in intra-myocardial 
lipids accumulation [38]. It is hypothesized that the 
increased availability and uptake of lipids and fatty 
acids may exceed the rates of their use, resulting in lipid 
accumulation within the cardiomyocytes. It was also 
shown that hyperglycemia decreases the expression of 
the peroxisome proliferator-activated receptors alpha 
(PPAR ) and their regulating genes [39]. Thus, prolonged 
exposure to hyperglycemia leads to the inhibition of 
fatty acids metabolism, which eventually leads to the 
increased deposition of lipids within the cardiac cells 
[40]. Excessive lipids and fatty acids deposition induces 
Reactive Oxygen Species accumulation, iNOS, and 
apoptosis, which then result in contractile dysfunction 
through increasing the intracellular ceramide levels. 
Lipid deposition may also induce contractile dysfunction 
through other mechanisms independent from ceramide, 
such as chronic activation of Protein Kinase-C (PKCs). 
Indeed, targeted over-expression of PKCß2 in the 
myocardium causes cardiomyopathy.
A number of studies determined the mean HOMA-IR in 
patients with and without renal disease who may or may 
not develop a CVD event (Table 2). Mean HOMA-IR in 
the general population was reported to vary from 1.39 to 
2.9, based on the assay of insulin used. On the other hand, 
Hanley et al demonstrated a HOMA-IR hazard ratio of 
2.5 in non-renal patients who develop a CVD event. A 
similarly increased hazard ratio of 1.6 was demonstrated 
in patients with diabetes who developed a CVD event 
while they had normal kidney function. However, the 
prevalence and hazard ratio of HOMA-IR were shown to 
be much higher in the CKD population.
After a follow-up period of approximately 5.5 years, the 
hazard ratio of cardiovascular mortalities in CKD patients 
was 2.6 (95% CI, 1.12 to 6.01) in the univariate Cox 
proportional hazards model of 183 non-diabetic patients 
with ESRD treated with maintenance hemodialysis. In the 
multivariate Cox models, the HR was 4.60 (95% CI, 1.83 
to 11.55) and was independent of age, C-reactive protein, 
and the presence of pre-existing vascular complications 
[3]. 
Treatment of insulin resistance in renal 
patients
Although IR is prevalent and has deleterious effects in 
renal patients, no guidelines are available to deal with 
those patients. Measures in the general population 
couldn’t be applied to renal patients, however. For 
example metformin, an efficient drug improving IR in the 
general population is contraindicated in CKD patients. 
Therefore, we tried in this review to locate suitable 
treatment options as follow:
1. Dietary restriction
Higher BMI is an independent predictor of CKD; in 
part through increased IR [48]. Dietary restriction 
improves HOMA-IR in the general population [49]. In 
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CKD patients, protein restriction reduces the production 
of nitrogenous compounds which may increase IR. On 
the other hand, dietary restriction may have deleterious 
effects and obesity provide a survival advantage for 
patients with ESRD [50, 51]. 
2. Exercise 
There is no doubt that exercise improves IR. The same is 
applied to ESRD patients on HD. Renal patients, however 
have limited physical function [52]. Actually, they have 
only half the exercise capacity of the normal sedentary 
individuals [53]. In addition, the increased CVD risk in 
this population could be aggravated by exercise.
In spite of these limitations a multidisciplinary program 
combining diet and exercise suggests that significant 
weight loss and improved physical functioning can be 
achieved in CKD patients [54].
3. Treatment of contributing factors
a. Treatment of anemia
Correction of anemia by erythropoietin [55] or intravenous 
iron [56] in HD patients showed an improvement of 
insulin sensitivity. This improvement may be due to 
improved exercise tolerance.
b. Treatment of vitamin D deficiency
Insulin sensitivity was normalized after 3 months of 
intravenous calcitriol treatment in uremic patients. 
Serum 1,25-(OH)2 D 3 levels in vitamin-D-deficient 
renal patients could be raised indirectly by correction of 
metabolic acidosis.
4. Thiazolidinediones 
Glitazones is a relatively new anti-diabetic group of 
drugs known to improve IR [57]. CKD patients treated 
with pioglitazone are less likely to develop end point 
of all-cause death, and specifically CVD mortality 
independent of the severity of renal impairment [58]. 
Although these drugs could be used in renal patients 
without dose adjustment, some rare adverse events, 
(weight gain, oedema, fluid retention, etc.), may limit 
their use in some patients [59]. However, concerns about 
the safety of this group had been raised. For example, 
rosiglitazone treatment increased the risk of myocardial 
infarction [60] and troglitazone, have been already 
withdrawn from the market due to hepatotoxicity.
5. Dialysis
Defronzo et al showed that dialysis of renal patients thrice 
weekly for 10 weeks normalizes IR. This improvement is 
correlated with the dialysis dose [61]. Similarly, peritoneal 
dialysis is as efficient as HD as regard to IR [22].
Measurement of IR
There are several arguments for recommending the 
routine measurement of serum insulin in renal patients 
(Table 3). IR is measured from the relationship between 
the sugar and the concomitant insulin level. Measurement 
of serum insulin level by the ELISA method is readily 
available and is not costly. Abnormal glucose level alone 
may not identify patients with increased IR, particularly 
in non-diabetic individuals. On the other hand, intensive 
blood glucose control doesn’t improve CVD outcome in 
diabetic patients. 
The main limitation for measurement of insulin in 
routine practice is the lack of standardization of insulin 
immunoassay. In 2007, the American Diabetic Association 
compared 12 commercially available methods to measure 
insulin [62]. They reported that, although all the methods 
were specific to insulin, there was a very high range of 
within-assay coefficient of variation (CVs) [3.7 – 39%] 
and among-assay CVs [12 – 66%], even with the use of a 
common insulin preparation. Some of the kits cross-react 
with intact pro-insulin and split it at different degrees. 
Conclusion
IR is a treatable disease [63] that predicts future 
cardiovascular events in both renal and non-renal 
patients. It is more prevalent in patients with renal 
disease, particularly those with previous CVD. The 
Table 3: Reasons to justify measurement of  insulin resistance in the renal patient
Reasons to measure insulin in the renal patient
1. Serum insulin is easy to be measured
2. IR is elevated in CKD patients
3. IR can predict CVD and DM in the general population
4. IR accelerates rate of decline in renal function
5. IR predict New Onset of Diabetes After Transplantation (NODAT) (Data accepted for publication)
6. Elevated IR can be managed by weight reduction, increased physical activity, and pharmacological treatment
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above evidence supports the general notion that IR 
has a deleterious effect on the progression of kidney 
disease. It also supports the recommendation to measure 
IR in clinical practice to identify patients at risk for 
future cardiovascular events, particularly those with 
renal diseases. This notion is supported by the ease of 
measurement of both serum glucose and insulin levels. IR 
can be modified by pharmacological therapy, increased 
physical activity, and by weight reduction. 
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